ArticleAntimicrobial agents and chemotherapy2024
Efficacy of epetraborole against
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07301320 (A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Prospective, Investigator-Initiated Trial to Assess the Efficacy, Safety, and Pharmacokinetics of Epetraborole in Patients With Mycobacterium Abscessus Lung Disease), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Prospective, Investigator-Initiated Trial to Assess the Efficacy, Safety, and Pharmacokinetics of Epetraborole in Patients With Mycobacterium Abscessus Lung Disease: REBOUND Study
Who cites it
9 citing papers in PubMed.
- CRISPRi-mediatedAntimicrobial agents and chemotherapy · 2026Article
- In vitro and in vivo activity of eravacycline against Mycobacterium abscessus.BMC microbiology · 2026Article
- Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease.The Journal of antimicrobial chemotherapy · 2026Article
- CRISPRi-mediated validation of candidatebioRxiv : the preprint server for biology · 2025Article
- A BALB/c mouse model of Mycobacterium abscessus lung infection based on once-weekly cyclophosphamide administration.Disease models & mechanisms · 2025Article
- Activity of combinations of bactericidal and bacteriostatic compounds inFrontiers in microbiology · 2025Review
- Toward better cures forClinical microbiology reviews · 2024Review
- Unlocking the Mycobacteroides abscessus pan-genome using computational tools: insights into evolutionary dynamics and lifestyle.Antonie van Leeuwenhoek · 2024Article
- Oral oxaborole MRX-5 exhibits efficacy against pulmonaryAntimicrobial agents and chemotherapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.